Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Sanofi Buys Out Arixtra Joint Venture With Organon; Expanded Label Coming

  • News

Executive Summary

Sanofi-Synthelabo is taking over sole rights to Arixtra from Organon ahead of an expected label expansion for the antithrombotic agent

You may also be interested in...



GSK Will Buy Arixtra From Sanofi If Aventis Merger Goes Through

GlaxoSmithKline's conditional acquisition of Sanofi's antithrombotic brands would give GSK an almost free chance to build a potentially significant new product line in the U.S

GSK Will Buy Arixtra From Sanofi If Aventis Merger Goes Through

GlaxoSmithKline's conditional acquisition of Sanofi's antithrombotic brands would give GSK an almost free chance to build a potentially significant new product line in the U.S

Sanofi/Aventis Merger Would Create Top 10 U.S. Pharma Company

A Sanofi/Aventis merger combination would break Sanofi into the top 10 ranking of U.S. pharmaceutical companies

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works

ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages

Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug

See All
UsernamePublicRestriction

Register

PS043145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By